3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol

3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol Basic information
Product Name:3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol
Synonyms:3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol;3,3,-(2,4-diaminopteridine-6,7-diyl)diphenol;TG100-115;TG100115;TG100 115;6,7-Bis(3-hydroxyphenyl)pteridine-2,4-diamine;3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol TG100-115;TG100-115, >=98%;TG100115; TG100 115;CS-427
CAS:677297-51-7
MF:C18H14N6O2
MW:346.34
EINECS:
Product Categories:Inhibitors;Akt;mTOR;PI3K;APIs
Mol File:677297-51-7.mol
3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol Structure
3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol Chemical Properties
Boiling point 699.6±65.0 °C(Predicted)
density 1.516±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility insoluble in H2O; insoluble in EtOH; ≥3.46 mg/mL in DMSO
form Yellow powder solid.
pka8.54±0.10(Predicted)
Safety Information
MSDS Information
3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol Usage And Synthesis
UsesTG100-115 is a potent and selective phosphoinositide 3-kinase gamma/delta (PI3Kγ/δ) inhibitor. It can provide potent cardioprotection, reduce infarct development, and preserve myocardial function.
DefinitionChEBI: 3-[2,4-diamino-7-(3-hydroxyphenyl)-6-pteridinyl]phenol is a member of pteridines.
Biological Activitytg100-115 is an inhibitor of pi3kγ and pi3kδ with ic50 values of 83 nm and 235 nm, respectively. tg100-115 shows no obvious activity against pi3kα and pi3kβ [1].tg100-115 remarkably reduced eosinophil accumulation, balf levels of classic th2 cytokine il-13, perivascular and peribronchial leukocyte accumulations, and bronchiolar mucin accumulation in a murine model. besides, tg100-115 showed to reduce airway hyper-responsiveness (ahr) by approximately 50% in asthmatic mice. moreover, tg100-115 has been reported to reduce both smoke-and lps-induced neutrophil and lps-induced classic th1 cytokine tnfα accumulations in mice [2].
targetPI3K-γ
references[1] doukas j1, wrasidlo w, noronha g, dneprovskaia e, fine r, weis s, hood j, demaria a, soll r, cheresh d. hosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. proc natl acad sci u s a. 2006 dec 26;103(52):19866-71.
[2] doukas j1, eide l, stebbins k, racanelli-layton a, dellamary l, martin m, dneprovskaia e, noronha g, soll r, wrasidlo w, acevedo lm, cheresh da. aerosolized phosphoinositide 3-kinase gamma/delta inhibitor tg100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. j pharmacol exp ther. 2009 mar;328(3):758-65.
3,3'-(2,4-Diamino-6,7-pteridinediyl)bisphenol Preparation Products And Raw materials
Rapamycin AC480 (BMS-599626) N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide Brivanib alaninate CUDC-101 RO4929097 Avagacestat (BMS-708163) IPI 145 Telaprevir SGX-523 Torin 1 5-[[4-(4-Pyridinyl)-6-quinolinyl]methylene]-2,4-thiazolidenedione (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid Tariquidar CCT 137690 CZC24832 Selumetinib Capmatinib

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.